Literature DB >> 7356892

Metabolism of salicylate during chronic aspirin therapy.

R H Rumble, P M Brooks, M S Roberts.   

Abstract

1. The effects of chronic administration of aspirin in therapeutic doses (3.9 g/day) on plasma and salivary salicylate levels were studied in eight subjects. 2. The urinary excretion profile for free salicylic acid and metabolites of salicylate were examined. 3. Plasma and salivary salicylate levels declined significantly after peak levels were achieved between days 3 and 10. 4. The decline in plasma and salivary salicylate levels may be due to an induction of a metabolic pathway such as salicylurate formation (Furst, Gupta & Paulus, 1977). Only the mean fraction of salicylate excreted as salicylurate appears to increase with time during the present study, although the change was not significant statistically. 5. The decline in plasma and salivary salicylate levels during chronic therapy may lead to an apparent 'tolerance' of some rheumatoid patients to aspirin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7356892      PMCID: PMC1429927          DOI: 10.1111/j.1365-2125.1980.tb04794.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man.

Authors:  G Levy; T Tsuchiya; L P Amsel
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

2.  Pharmacokinetics of tolbutamide: prediction by concentration in saliva.

Authors:  S B Matin; S H Wan; J H Karam
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

3.  Relationship between dose and apparent volume of distribution of salicylate in children.

Authors:  G Levy; S J Yaffe
Journal:  Pediatrics       Date:  1974-12       Impact factor: 7.124

4.  Salicylate accumulation kinetics in man.

Authors:  G Levy; T Tsuchiya
Journal:  N Engl J Med       Date:  1972-08-31       Impact factor: 91.245

5.  Drug biotransformation interactions in man. I. Mutual inhibition in glucuronide formation of salicylic acid and salicylamide in man.

Authors:  G Levy; J A Procknal
Journal:  J Pharm Sci       Date:  1968-08       Impact factor: 3.534

6.  Capacity-limited salicylurate formation during prolonged administration of aspirin to healthy human subjects.

Authors:  G Levy; A W Vogel; L P Amsel
Journal:  J Pharm Sci       Date:  1969-04       Impact factor: 3.534

7.  Variations of serum concentrations and half-life of salicylate in patients with rheumatoid arthritis.

Authors:  H E Paulus; M Siegel; E Mongan; R Okun; J J Calabro
Journal:  Arthritis Rheum       Date:  1971 Jul-Aug

8.  Determination of acetylsalicylic acid and salicylic acid in plasma.

Authors:  M Rowland; S Riegelman
Journal:  J Pharm Sci       Date:  1967-06       Impact factor: 3.534

9.  Application of salivary salicylate data to biopharmaceutical studies of salicylates.

Authors:  G Graham; M Rowland
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534

10.  Kinetics of salicylate metabolism.

Authors:  T Gibson; G Zaphiropoulos; J Grove; B Widdop; D Berry
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

View more
  11 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  The effect of concurrent aspirin upon plasma concentrations of tenoxicam.

Authors:  R O Day; P D Paull; S Lam; B R Swanson; K M Williams; D N Wade
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 3.  Adverse reactions and interactions with aspirin. Considerations in the treatment of the elderly patient.

Authors:  J Karsh
Journal:  Drug Saf       Date:  1990 Sep-Oct       Impact factor: 5.606

Review 4.  Salicylate intoxication in the elderly. Recognition and recommendations on how to prevent it.

Authors:  C Durnas; B J Cusack
Journal:  Drugs Aging       Date:  1992 Jan-Feb       Impact factor: 3.923

5.  Salicylate pharmacokinetics in patients with rheumatoid arthritis.

Authors:  S G Owen; M S Roberts; W T Friesen; H W Francis
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

6.  Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates.

Authors:  R O Day; D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

7.  Monitoring plasma concentrations of salicylate.

Authors:  M Mandelli; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of the salicylates.

Authors:  C J Needs; P M Brooks
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 9.  Drug structure-transport relationships.

Authors:  Michael S Roberts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-24       Impact factor: 2.745

10.  Correlation between long-term aspirin use and F-fluorodeoxyglucose uptake in colorectal cancer measured by PET/CT.

Authors:  Binbin Su; Baixuan Xu; Jun Wan
Journal:  PLoS One       Date:  2014-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.